Table 1 CSF and serum sample characteristics and assayed methods.
From: Neurofilament light chain levels correlate with clinical measures in CLN3 disease
Group | Age (years) | Sex, n (%) | Assay method | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
n | Median | Range | Female | Male | CSF | Serum | ||||
Q1 | Q3 | Full | PEA | ELISA | SimoaTM | |||||
CLN3 | 21 | 11.4 | 7.8 | 15.4 | 6.8–20.7 | 10 (48) | 11 (52) | ✓ | ✓ | ✓ |
Comparators (n) | 32 | 33 | 34 | |||||||
Pediatric laboratory controls | 20 | 12.5 | 7.5 | 15.5 | 3.0–20.0 | 10 (50) | 10 (50) | ✓ | ||
PLC subset | 9 | 14.0 | 7.0 | 17.0 | 4.8–20.0 | 2 (22) | 7 (78) | ✓ | ✓ | |
Pediatric healthy siblings | 10 | 10.8 | 9.4 | 13.3 | 6.3–18.7 | 4 (40) | 6 (60) | ✓ | ||
CTD | 12 | 7.0 | 3.9 | 10.8 | 3.2–14.3 | 0 | 12 | ✓ | ✓ | ✓ |
SLOS | 12 | 9.4 | 5.2 | 13.7 | 2.6–21.0 | 5 (42) | 7 (58) | ✓ | ✓ | |
